Considering a recent report pointing at RNASET2 as a candidate biomarker for low vs. high-grade PCa [40], we chose two cell lines (PC-3 and 22Rv1) representing poorly and highly aggressive forms of this tumor type, respectively, to investigate putative differences in their response to RNASET2 modulation. Here, RNASET2 is linked to posterior cortical atrophy.